Source comparison
MK-677 Study Evidence vs Marketing Claims — The Gap
Here's the honest answer: no published MK-677 study has ever demonstrated the dramatic muscle-building or fat-loss results that supplement retailers claim. Not one. The largest body composition change in any published trial was 1.8kg lean mass over 12 months.
This comparison does not assign a generated winner or score.
- Here's the honest answer: no published MK-677 study has ever demonstrated the dramatic muscle-building or fat-loss results that supplement retailers claim. Not one. The largest body composition change in any published trial was 1.8kg lean mass over 12 months. Modest, measurable, but nowhere near the 10–15 pound muscle gains marketed on peptide supplier websites.
- What the MK-677 study data does show: meaningful improvements in bone density (measured via DEXA in the two-year trial), modest improvements in sleep quality (secondary endpoint in multiple trials), and sustained IGF-1 elevation without the safety risks of exogenous GH. These are real, clinically validated outcomes. They're just not the transformative physique changes that drive supplement sales.
- The gap exists because IGF-1 elevation alone doesn't guarantee anabolism. Muscle protein synthesis requires adequate protein intake (1.6–2.2g per kg body weight), progressive mechanical tension (resistance training), and caloric surplus or at minimum maintenance. MK-677 provides one input. Elevated anabolic signaling. But without the other inputs, the effect is marginal. This is why bodybuilding forums report wildly variable results: responders are those already optimizing diet and training. Non-responders expect the compound to work independently.
- Research-grade MK-677 sourced from verified synthesis facilities ensures dosing accuracy, but even perfect compound purity won't override poor training structure. The MK-677 study literature is clear: the compound is an adjunct, not a replacement.